BioCryst Announces Strong Q3 2024 Revenue Growth
PremiumCompany AnnouncementsBioCryst Announces Strong Q3 2024 Revenue Growth
12d ago
BioCryst reports Q3 EPS (7c), consensus (6c)
Premium
The Fly
BioCryst reports Q3 EPS (7c), consensus (6c)
12d ago
BioCryst sees FY24 ORLADEYO revenue $430M-$435M
Premium
The Fly
BioCryst sees FY24 ORLADEYO revenue $430M-$435M
12d ago
Two Key Products Drive BioCryst (BCRX) to New Highs
PremiumMarket NewsTwo Key Products Drive BioCryst (BCRX) to New Highs
1M ago
BioCryst reports inducement grants under Nasdaq listing rule
Premium
The Fly
BioCryst reports inducement grants under Nasdaq listing rule
1M ago
BioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment
Premium
Company Announcements
BioCryst Begins Phase 1 Trial for Netherton Syndrome Treatment
2M ago
BioCryst presents first interim real-word evidence from APeX-N trial
PremiumThe FlyBioCryst presents first interim real-word evidence from APeX-N trial
2M ago
BioCryst appoints Fong as Chief Medical Officer
Premium
The Fly
BioCryst appoints Fong as Chief Medical Officer
2M ago
BioCryst reports inducement grants under Nasdaq listing rule
Premium
The Fly
BioCryst reports inducement grants under Nasdaq listing rule
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100